-
1
-
-
0030944023
-
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
-
J. Simons, E. Jaffee, C. Weber Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537 1546 (Pubitemid 27175572)
-
(1997)
Cancer Research
, vol.57
, Issue.8
, pp. 1537-1546
-
-
Simons, J.W.1
Jaffee, E.M.2
Weber, C.E.3
Levitsky, H.I.4
Nelson, W.G.5
Carducci, M.A.6
Lazenby, A.J.7
Cohen, L.K.8
Finn, C.C.9
Clift, S.M.10
Hauda, K.M.11
Beck, L.A.12
Leiferman, K.M.13
Owens Jr., A.H.14
Piantadosi, S.15
Dranoff, G.16
Mulligan, R.C.17
Pardoll, D.M.18
Marshall, F.F.19
-
2
-
-
0032503016
-
Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
-
M.C. Thomas, T.F. Greten, D.M. Pardoll, E.M. Jaffee Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine Hum Gene Ther 9 1998 835 843 (Pubitemid 28197370)
-
(1998)
Human Gene Therapy
, vol.9
, Issue.6
, pp. 835-843
-
-
Thomas, M.C.1
Greten, T.F.2
Pardoll, D.M.3
Jaffee, E.M.4
-
3
-
-
33750586798
-
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
-
DOI 10.1200/JCO.2005.05.5335
-
J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730 (Pubitemid 46630936)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.29
, pp. 4721-4730
-
-
Nemunaitis, J.1
Dillman, R.O.2
Schwarzenberger, P.O.3
Senzer, N.4
Cunningham, C.5
Cutler, J.6
Tong, A.7
Kumar, P.8
Pappen, B.9
Hamilton, C.10
DeVol, E.11
Maples, P.B.12
Liu, L.13
Chamberlin, T.14
Shawler, D.L.15
Fakhrai, H.16
-
4
-
-
3543060047
-
+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
-
DOI 10.1084/jem.20031435
-
A. Thomas, L. Santarsiero, E. Lutz Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients J Exp Med 200 2004 297 306 (Pubitemid 39031249)
-
(2004)
Journal of Experimental Medicine
, vol.200
, Issue.3
, pp. 297-306
-
-
Thomas, A.M.1
Santarsiero, L.M.2
Lutz, E.R.3
Armstrong, T.D.4
Chen, Y.-C.5
Huang, L.-Q.6
Laheru, D.A.7
Goggins, M.8
Hruban, R.H.9
Jaffee, E.M.10
-
5
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
G. Dranoff, E. Jaffee, A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543 (Pubitemid 23111402)
-
(1993)
Proceedings of the National Academy of Sciences of the United States of America
, vol.90
, Issue.8
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
Golumbek, P.4
Levitsky, H.5
Brose, K.6
Jackson, V.7
Hamada, H.8
Pardoll, D.9
Mulligan, R.C.10
-
6
-
-
0032573225
-
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
-
R. Soiffer, T. Lynch, M. Mihm Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proc Natl Acad Sci U S A 95 1998 13141 13146
-
(1998)
Proc Natl Acad Sci U S A
, vol.95
, pp. 13141-13146
-
-
Soiffer, R.1
Lynch, T.2
Mihm, M.3
-
7
-
-
0036813199
-
GM-CSF-based cancer vaccines
-
DOI 10.1034/j.1600-065X.2002.18813.x
-
G. Dranoff GM-CSF-based cancer vaccines Immunol Rev 188 2002 147 154 (Pubitemid 35398872)
-
(2002)
Immunological Reviews
, vol.188
, pp. 147-154
-
-
Dranoff, G.1
-
8
-
-
0035152718
-
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase i trial of safety and immune activation
-
Jaffee E, Hruban R, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 200;19;145-56.
-
(2001)
J Clin Oncol
, vol.9
, pp. 45-56
-
-
Jaffee, E.1
Hruban, R.2
Biedrzycki, B.3
-
9
-
-
79151486551
-
A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation
-
E. Lutz, C.J. Yeo, K.D. Lillemoe A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335
-
(2011)
Ann Surg
, vol.253
, pp. 328-335
-
-
Lutz, E.1
Yeo, C.J.2
Lillemoe, K.D.3
-
11
-
-
79955547695
-
CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity
-
H. Shirota, D.M. Klinman CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity Cancer Immunol Immunother 60 2011 659 669
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 659-669
-
-
Shirota, H.1
Klinman, D.M.2
-
12
-
-
0037439696
-
CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma
-
A.D. Sandler, H. Chihara, G. Kobayashi CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res 63 2003 394 399 (Pubitemid 36152498)
-
(2003)
Cancer Research
, vol.63
, Issue.2
, pp. 394-399
-
-
Sandler, A.D.1
Chihara, H.2
Kobayashi, G.3
Zhu, X.4
Miller, M.A.5
Scott, D.L.6
Krieg, A.M.7
-
13
-
-
4644254242
-
Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides
-
K. Hiraoka, S. Yamamoto, S. Otsuru Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides J Immunol 173 2004 4297 4307 (Pubitemid 39280657)
-
(2004)
Journal of Immunology
, vol.173
, Issue.7
, pp. 4297-4307
-
-
Hiraoka, K.1
Yamamoto, S.2
Otsuru, S.3
Nakai, S.4
Tamai, K.5
Morishita, R.6
Ogihara, T.7
Kaneda, Y.8
-
14
-
-
70450227479
-
CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic applications in cancer
-
Y.M. Murad, T.M. Clay CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer BioDrugs 23 2009 361 375
-
(2009)
BioDrugs
, vol.23
, pp. 361-375
-
-
Murad, Y.M.1
Clay, T.M.2
-
15
-
-
33751371759
-
+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10
-
DOI 10.1007/s00262-006-0160-8
-
N. Larmonier, M. Marron, Y. Zeng Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10 Cancer Immunol Immunother 56 2007 48 59 (Pubitemid 44812446)
-
(2007)
Cancer Immunology, Immunotherapy
, vol.56
, Issue.1
, pp. 48-59
-
-
Larmonier, N.1
Marron, M.2
Zeng, Y.3
Cantrell, J.4
Romanoski, A.5
Sepassi, M.6
Thompson, S.7
Chen, X.8
Andreansky, S.9
Katsanis, E.10
-
16
-
-
27644457376
-
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
-
DOI 10.1016/j.ccr.2005.10.012, PII S1535610805003314
-
D.A. Thomas, J. Massagué TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 8 2005 369 380 (Pubitemid 41579832)
-
(2005)
Cancer Cell
, vol.8
, Issue.5
, pp. 369-380
-
-
Thomas, D.A.1
Massague, J.2
-
17
-
-
0348223787
-
+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
-
DOI 10.1084/jem.20030152
-
+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 J Exp Med 198 2003 1875 1886 (Pubitemid 38032120)
-
(2003)
Journal of Experimental Medicine
, vol.198
, Issue.12
, pp. 1875-1886
-
-
Chen, W.1
Jin, W.2
Hardegen, N.3
Lei, K.-J.4
Li, L.5
Marinos, N.6
McGrady, G.7
Wahl, S.M.8
-
18
-
-
78751503892
-
Phase i trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine
-
J. Olivares, P. Kumar, Y. Yu Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine Clin Cancer Res 17 2011 183 192
-
(2011)
Clin Cancer Res
, vol.17
, pp. 183-192
-
-
Olivares, J.1
Kumar, P.2
Yu, Y.3
-
19
-
-
33751047033
-
Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma
-
DOI 10.1038/sj.cgt.7700975, PII 7700975
-
H. Fakhrai, J.C. Mantil, L. Liu Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma Cancer Gene Ther 13 2006 1052 1060 (Pubitemid 44760103)
-
(2006)
Cancer Gene Therapy
, vol.13
, Issue.12
, pp. 1052-1060
-
-
Fakhrai, H.1
Mantil, J.C.2
Liu, L.3
Nicholson, G.L.4
Murphy-Satter, C.S.5
Ruppert, J.6
Shawler, D.L.7
-
20
-
-
78449237498
-
Signaling through OX40 enhances antitumor immunity
-
S.M. Jensen, L.D. Maston, M.J. Gough Signaling through OX40 enhances antitumor immunity Semin Oncol 37 5 2010 Oct 524 532
-
(2010)
Semin Oncol
, vol.37
, Issue.5
, pp. 524-532
-
-
Jensen, S.M.1
Maston, L.D.2
Gough, M.J.3
-
21
-
-
66049113612
-
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
-
D. Hirschhorn-Cymerman, G.A. Rizzuto, T. Merghoub OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis J Exp Med 206 2009 1103 1116
-
(2009)
J Exp Med
, vol.206
, pp. 1103-1116
-
-
Hirschhorn-Cymerman, D.1
Rizzuto, G.A.2
Merghoub, T.3
-
22
-
-
36048956341
-
+ Th cell antitumor immunity in mice
-
DOI 10.1172/JCI32693
-
+ Th cell antitumor immunity in mice J Clin Invest 117 2007 3330 3338 (Pubitemid 350096989)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.11
, pp. 3330-3338
-
-
Zaini, J.1
Andarini, S.2
Tahara, M.3
Saijo, Y.4
Ishii, N.5
Kawakami, K.6
Taniguchi, M.7
Sugamura, K.8
Nukiwa, T.9
Kikuchi, T.10
-
23
-
-
30744445700
-
+ T cell tolerance to an endogenous tumor antigen
-
+ T cell tolerance to an endogenous tumor antigen J Immunol 176 2006 974 983 (Pubitemid 43099696)
-
(2006)
Journal of Immunology
, vol.176
, Issue.2
, pp. 974-983
-
-
Murata, S.1
Ladle, B.H.2
Kim, P.S.3
Lutz, E.R.4
Wolpoe, M.E.5
Ivie, S.E.6
Smith, H.M.7
Armstrong, T.D.8
Emens, L.A.9
Jaffee, E.M.10
Reilly, R.T.11
-
24
-
-
23944461007
-
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with Anti-OX40 and Anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice
-
DOI 10.1002/ijc.21098
-
C. Cuadros, A.L. Dominguez, P.L. Lollini Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 116 2005 934 943 (Pubitemid 41209201)
-
(2005)
International Journal of Cancer
, vol.116
, Issue.6
, pp. 934-943
-
-
Cuadros, C.1
Dominguez, A.L.2
Lollini, P.-L.3
Croft, M.4
Mittler, R.S.5
Borgstrom, P.6
Lustgarten, J.7
-
25
-
-
78449262545
-
Biology and clinical applications of CD40 in cancer treatment
-
E. Fonsatti, M. Maio, M. Altomonte, P. Hersey Biology and clinical applications of CD40 in cancer treatment Semin Oncol 37 2010 517 523
-
(2010)
Semin Oncol
, vol.37
, pp. 517-523
-
-
Fonsatti, E.1
Maio, M.2
Altomonte, M.3
Hersey, P.4
-
26
-
-
77956462624
-
Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
-
M.R. Sorensen, P.J. Holst, M.A. Steffensen, J.P. Christensen, A.R. Thomsen Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model Vaccine 28 2010 6757 6764
-
(2010)
Vaccine
, vol.28
, pp. 6757-6764
-
-
Sorensen, M.R.1
Holst, P.J.2
Steffensen, M.A.3
Christensen, J.P.4
Thomsen, A.R.5
-
27
-
-
78549256115
-
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase i study of patients with advanced solid tumors
-
J. Rüter, S.J. Antonia, H.A. Burris, R.D. Huhn, R.H. Vonderheide Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors Cancer Biol Ther 10 2010 983 993
-
(2010)
Cancer Biol Ther
, vol.10
, pp. 983-993
-
-
Rüter, J.1
Antonia, S.J.2
Burris, H.A.3
Huhn, R.D.4
Vonderheide, R.H.5
-
28
-
-
33846602242
-
A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease
-
DOI 10.1245/s10434-006-9196-4
-
S. Dessureault, D. Noyes, D. Lee A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease Ann Surg Oncol 14 2007 869 884 (Pubitemid 46175338)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.2
, pp. 869-884
-
-
Dessureault, S.1
Noyes, D.2
Lee, D.3
Dunn, M.4
Janssen, W.5
Cantor, A.6
Sotomayor, E.7
Messina, J.8
Antonia, S.J.9
-
29
-
-
79953154967
-
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans
-
G.L. Beatty, E.G. Chiorean, M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
-
(2011)
Science
, vol.331
, pp. 1612-1616
-
-
Beatty, G.L.1
Chiorean, E.G.2
Fishman, M.P.3
-
30
-
-
35549005142
-
+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine
-
DOI 10.1158/1078-0432.CCR-07-0258
-
F. Orlandi, F.M. Venanzi, A. Concetti Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine Clin Cancer Res 13 2007 6195 6203 (Pubitemid 350075081)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.20
, pp. 6195-6203
-
-
Orlandi, F.1
Venanzi, F.M.2
Concetti, A.3
Yamauchi, H.4
Tiwari, S.5
Norton, L.6
Wolchok, J.D.7
Houghton, A.N.8
Gregor, P.D.9
-
31
-
-
0035116901
-
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
-
R.T. Reilly, J.P. Machiels, L.A. Emens The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors Cancer Res 61 2001 880 883 (Pubitemid 32174395)
-
(2001)
Cancer Research
, vol.61
, Issue.3
, pp. 880-883
-
-
Todd Reilly, R.1
Machiels, J.-P.H.2
Emens, L.A.3
Ercolini, A.M.4
Okoye, F.I.5
Lei, R.Y.6
Weintraub, D.7
Jaffee, E.M.8
-
32
-
-
0043136619
-
+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
-
+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice J Immunol 171 2003 2161 2169 (Pubitemid 36966500)
-
(2003)
Journal of Immunology
, vol.171
, Issue.4
, pp. 2161-2169
-
-
Wolpoe, M.E.1
Lutz, E.R.2
Ercolini, A.M.3
Murata, S.4
Ivie, S.E.5
Garrett, E.S.6
Emens, L.A.7
Jaffee, E.M.8
Reilly, R.T.9
-
33
-
-
43049144967
-
+ T cell responses in mice through Fc-mediated activation of DCs
-
DOI 10.1172/JCI34333
-
P. Kim, T. Armstrong, H. Song Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs J Clin Invest 118 2008 1700 1711 (Pubitemid 351632374)
-
(2008)
Journal of Clinical Investigation
, vol.118
, Issue.5
, pp. 1700-1711
-
-
Kim, P.S.1
Armstrong, T.D.2
Song, H.3
Wolpoe, M.E.4
Weiss, V.5
Manning, E.A.6
Huang, L.Q.7
Murata, S.8
Sgouros, G.9
Emens, L.A.10
Reilly, R.T.11
Jaffee, E.M.12
-
35
-
-
78049427830
-
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape
-
R.L. Ferris, E.M. Jaffee, S. Ferrone Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 2010 4390 4399
-
(2010)
J Clin Oncol
, vol.28
, pp. 4390-4399
-
-
Ferris, R.L.1
Jaffee, E.M.2
Ferrone, S.3
-
36
-
-
31544446098
-
Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells
-
DOI 10.1158/0008-5472.CAN-05-2429
-
J.M. Roda, R. Parihar, C. Magro, G.J. Nuovo, S. Tridandapani, W.E. Carson 3rd Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells Cancer Res 66 2006 517 526 (Pubitemid 43166061)
-
(2006)
Cancer Research
, vol.66
, Issue.1
, pp. 517-526
-
-
Roda, J.M.1
Parihar, R.2
Magro, C.3
Nuovo, G.J.4
Tridandapani, S.5
Carson III, W.E.6
-
37
-
-
78650385895
-
Active immunotherapy induces antibody responses that target tumor angiogenesis
-
J. Schoenfeld, M. Jinushi, Y. Nakazaki Active immunotherapy induces antibody responses that target tumor angiogenesis Cancer Res 70 2010 10150 10160
-
(2010)
Cancer Res
, vol.70
, pp. 10150-10160
-
-
Schoenfeld, J.1
Jinushi, M.2
Nakazaki, Y.3
-
38
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
39
-
-
34447117552
-
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
-
DOI 10.1158/1078-0432.CCR-07-0374
-
E.A. Manning, J.G. Ullman, J.M. Leatherman A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism Clin Cancer Res 13 2007 3951 3959 (Pubitemid 47037603)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.13
, pp. 3951-3959
-
-
Manning, E.A.1
Ullman, J.G.M.2
Leatherman, J.M.3
Asquith, J.M.4
Hansen, T.R.5
Armstrong, T.D.6
Hicklin, D.J.7
Jaffee, E.M.8
Emens, L.A.9
-
40
-
-
0032741283
-
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
-
D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, D.P. Carbone Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin Cancer Res 5 1999 2963 2970 (Pubitemid 29493976)
-
(1999)
Clinical Cancer Research
, vol.5
, Issue.10
, pp. 2963-2970
-
-
Gabrilovich, D.I.1
Ishida, T.2
Nadaf, S.3
Ohm, J.E.4
Carbone, D.P.5
-
41
-
-
73349118752
-
Dendritic cell recovery post-lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination
-
M.L. Salem, D.J. Cole Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Cancer Immunol Immunother 59 2010 341 353
-
(2010)
Cancer Immunol Immunother
, vol.59
, pp. 341-353
-
-
Salem, M.L.1
Cole, D.J.2
-
42
-
-
0041975925
-
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
-
DOI 10.1002/eji.200324034
-
J. Ma, W.J. Urba, L. Si, Y. Wang, B.A. Fox, H.M. Hu Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution Eur J Immunol 33 2003 2123 2132 (Pubitemid 37010029)
-
(2003)
European Journal of Immunology
, vol.33
, Issue.8
, pp. 2123-2132
-
-
Ma, J.1
Urba, W.J.2
Si, L.3
Wang, Y.4
Fox, B.A.5
Hu, H.-M.6
-
43
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy
-
S.A. Rosenberg, J.C. Yang, R.M. Sherry Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy Clin Cancer Res 17 2011 4550 4557
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
-
44
-
-
34948820602
-
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
-
DOI 10.1038/nm1622, PII NM1622
-
L. Apetoh, F. Ghiringhelli, A. Tesniere Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 2007 1050 1059 (Pubitemid 47517504)
-
(2007)
Nature Medicine
, vol.13
, Issue.9
, pp. 1050-1059
-
-
Apetoh, L.1
Ghiringhelli, F.2
Tesniere, A.3
Obeid, M.4
Ortiz, C.5
Criollo, A.6
Mignot, G.7
Maiuri, M.C.8
Ullrich, E.9
Saulnier, P.10
Yang, H.11
Amigorena, S.12
Ryffel, B.13
Barrat, F.J.14
Saftig, P.15
Levi, F.16
Lidereau, R.17
Nogues, C.18
Mira, J.-P.19
Chompret, A.20
Joulin, V.21
Clavel-Chapelon, F.22
Bourhis, J.23
Andre, F.24
Delaloge, S.25
Tursz, T.26
Kroemer, G.27
Zitvogel, L.28
more..
-
45
-
-
0030966954
-
Sensitization of cancer cells treated with cytotoxic drugs to fas- mediated cytotoxicity
-
O. Micheau, E. Solary, A. Hammann, F. Martin, M.T. Dimanche-Boitrel Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity J Natl Cancer Inst 89 1997 783 789 (Pubitemid 27242279)
-
(1997)
Journal of the National Cancer Institute
, vol.89
, Issue.11
, pp. 783-789
-
-
Micheau, O.1
Solary, E.2
Hammann, A.3
Martin, F.4
Dimanche-Boitrel, M.-T.5
-
46
-
-
57749190791
-
Whole tumor cell vaccine with irradiated S180 cells as adjuvant
-
J. Li, A.V. King, S.L. Stickel Whole tumor cell vaccine with irradiated S180 cells as adjuvant Vaccine 27 2009 558 564
-
(2009)
Vaccine
, vol.27
, pp. 558-564
-
-
Li, J.1
King, A.V.2
Stickel, S.L.3
-
47
-
-
0036721629
-
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
-
U.K. Liyanage, T.T. Moore, H.G. Joo Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with breast or pancreas adenocarcinomas J Immunol 169 2002 2756 2761 (Pubitemid 34921025)
-
(2002)
Journal of Immunology
, vol.169
, Issue.5
, pp. 2756-2761
-
-
Liyanage, U.K.1
Moore, T.T.2
Joo, H.-G.3
Tanaka, Y.4
Herrmann, V.5
Doherty, G.6
Drebin, J.A.7
Strasberg, S.M.8
Eberlein, T.J.9
Goedegebuure, P.S.10
Linehan, D.C.11
-
48
-
-
77749252468
-
Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells
-
R. Liu, S. Xiong, L. Zhang, Y. Chu Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells Cell Mol Immunol 7 2010 157 162
-
(2010)
Cell Mol Immunol
, vol.7
, pp. 157-162
-
-
Liu, R.1
Xiong, S.2
Zhang, L.3
Chu, Y.4
-
49
-
-
21144454780
-
+ T cells to the antitumor immune response
-
DOI 10.1084/jem.20042167
-
A.M. Ercolini, B.H. Ladle, E.A. Manning Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 2005 1591 1602 (Pubitemid 40723662)
-
(2005)
Journal of Experimental Medicine
, vol.201
, Issue.10
, pp. 1591-1602
-
-
Ercolini, A.M.1
Ladle, B.H.2
Manning, E.A.3
Pfannenstiel, L.W.4
Armstrong, T.D.5
Machiels, J.-P.H.6
Bieler, J.G.7
Emens, L.A.8
Reilly, R.T.9
Jaffee, E.M.10
-
50
-
-
0035328683
-
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
-
J.P. Machiels, R.T. Reilly, L.A. Emens Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 2001 3689 3697 (Pubitemid 32694981)
-
(2001)
Cancer Research
, vol.61
, Issue.9
, pp. 3689-3697
-
-
Machiels, J.-P.H.1
Todd Reilly, R.2
Emens, L.A.3
Ercolini, A.M.4
Lei, R.Y.5
Weintraub, D.6
Okoye, F.I.7
Jaffee, E.M.8
-
51
-
-
79551514818
-
Cyclophosphamide induces differentiation of Th17 cells in cancer patients
-
S. Viaud, C. Flament, M. Zoubir Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Res 71 2011 661 665
-
(2011)
Cancer Res
, vol.71
, pp. 661-665
-
-
Viaud, S.1
Flament, C.2
Zoubir, M.3
-
52
-
-
40949157885
-
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
-
DOI 10.1158/1078-0432.CCR-07-0371
-
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 14 2008 1455 1463 (Pubitemid 351413929)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.5
, pp. 1455-1463
-
-
Laheru, D.1
Lutz, E.2
Burke, J.3
Biedrzycki, B.4
Solt, S.5
Onners, B.6
Tartakovsky, I.7
Nemunaitis, J.8
Le, D.9
Sugar, E.10
Hege, K.11
Jaffee, E.12
-
53
-
-
29444433283
-
Combining cancer vaccines with chemotherapy
-
DOI 10.1517/14656566.6.16.2813
-
G. Chong, M.A. Morse Combining cancer vaccines with chemotherapy Expert Opin Pharmacother 6 2005 2813 2820 (Pubitemid 43009544)
-
(2005)
Expert Opinion on Pharmacotherapy
, vol.6
, Issue.16
, pp. 2813-2820
-
-
Chong, G.1
Morse, M.A.2
-
54
-
-
77951086882
-
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
-
J. Vincent, G. Mignot, F. Chalmin 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 2010 3052 3061
-
(2010)
Cancer Res
, vol.70
, pp. 3052-3061
-
-
Vincent, J.1
Mignot, G.2
Chalmin, F.3
-
55
-
-
78349313304
-
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model
-
H.S. Kim, H.M. Park, J.S. Park Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model Vaccine 28 2010 7787 7796
-
(2010)
Vaccine
, vol.28
, pp. 7787-7796
-
-
Kim, H.S.1
Park, H.M.2
Park, J.S.3
-
56
-
-
77956680680
-
A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
-
K.N. Kodumudi, K. Woan, D.L. Gilvary, E. Sahakian, S. Wei, J.Y. Djeu A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers Clin Cancer Res 16 2010 4583 4594
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4583-4594
-
-
Kodumudi, K.N.1
Woan, K.2
Gilvary, D.L.3
Sahakian, E.4
Wei, S.5
Djeu, J.Y.6
-
57
-
-
77952549994
-
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
-
L.W. Pfannenstiel, S.S. Lam, L.A. Emens, E.M. Jaffee, T.D. Armstrong Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice Cell Immunol 263 2010 79 87
-
(2010)
Cell Immunol
, vol.263
, pp. 79-87
-
-
Pfannenstiel, L.W.1
Lam, S.S.2
Emens, L.A.3
Jaffee, E.M.4
Armstrong, T.D.5
-
58
-
-
33745612716
-
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
-
DOI 10.1007/s00262-005-0116-4
-
R.A. Prell, L. Gearin, A. Simmons, M. Vanroey, K. Jooss The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration Cancer Immunol Immunother 55 2006 1285 1293 (Pubitemid 43992054)
-
(2006)
Cancer Immunology, Immunotherapy
, vol.55
, Issue.10
, pp. 1285-1293
-
-
Prell, R.A.1
Gearin, L.2
Simmons, A.3
VanRoey, M.4
Jooss, K.5
-
59
-
-
73349084990
-
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation
-
L.A. Emens, J.M. Asquith, J.M. Leatherman Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation J Clin Oncol 27 2009 5911 5918
-
(2009)
J Clin Oncol
, vol.27
, pp. 5911-5918
-
-
Emens, L.A.1
Asquith, J.M.2
Leatherman, J.M.3
-
60
-
-
33745860066
-
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
-
J.J. Engelhardt, T.J. Sullivan, J.P. Allison CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism J Immunol 177 2006 1052 1061 (Pubitemid 44036607)
-
(2006)
Journal of Immunology
, vol.177
, Issue.2
, pp. 1052-1061
-
-
Engelhardt, J.J.1
Sullivan, T.J.2
Allison, J.P.3
-
62
-
-
0033517152
-
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
-
DOI 10.1084/jem.190.3.355
-
A. van Elsas, A.A. Hurwitz, J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366 (Pubitemid 29374833)
-
(1999)
Journal of Experimental Medicine
, vol.190
, Issue.3
, pp. 355-366
-
-
Van Elsas, A.1
Hurwitz, A.A.2
Allison, J.P.3
-
63
-
-
33745851479
-
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
-
DOI 10.1172/JCI27745
-
S.A. Quezada, K.S. Peggs, M.A. Curran, J.P. Allison CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells J Clin Invest 116 2006 1935 1945 (Pubitemid 44033317)
-
(2006)
Journal of Clinical Investigation
, vol.116
, Issue.7
, pp. 1935-1945
-
-
Quezada, S.A.1
Peggs, K.S.2
Curran, M.A.3
Allison, J.P.4
-
64
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
F.S. Hodi, S.J. O'Day, D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
65
-
-
0344341626
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
-
DOI 10.1073/pnas.0830997100
-
F.S. Hodi, M.C. Mihm, R.J. Soiffer Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712 4717 (Pubitemid 36457795)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.8
, pp. 4712-4717
-
-
Hodi, F.S.1
Mihm, M.C.2
Soiffer, R.J.3
Haluska, F.G.4
Butler, M.5
Seiden, M.V.6
Davis, T.7
Henry-Spires, R.8
MacRae, S.9
Willman, A.10
Padera, R.11
Jaklitsch, M.T.12
Shankar, S.13
Chen, T.C.14
Korman, A.15
Allison, J.P.16
Dranoff, G.17
-
66
-
-
77954899030
-
Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
J.R. Brahmer, C.G. Drake, I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
-
(2010)
J Clin Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
-
67
-
-
63449124514
-
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors
-
B. Li, M. VanRoey, C. Wang, T.H. Chen, A. Korman, K. Jooss Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors Clin Cancer Res 15 2009 1623 1634
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1623-1634
-
-
Li, B.1
Vanroey, M.2
Wang, C.3
Chen, T.H.4
Korman, A.5
Jooss, K.6
-
68
-
-
79956103042
-
Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors
-
S.F. Ngiow, B. von Scheidt, H. Akiba, H. Yagita, M.W. Teng, M.J. Smyth Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors Cancer Res 71 2011 3540 3551
-
(2011)
Cancer Res
, vol.71
, pp. 3540-3551
-
-
Ngiow, S.F.1
Von Scheidt, B.2
Akiba, H.3
Yagita, H.4
Teng, M.W.5
Smyth, M.J.6
-
69
-
-
36048963838
-
+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
-
DOI 10.1172/JCI31184
-
J.F. Grosso, C.C. Kelleher, T.J. Harris LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392 (Pubitemid 350096994)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.11
, pp. 3383-3392
-
-
Grosso, J.F.1
Kelleher, C.C.2
Harris, T.J.3
Maris, C.H.4
Hipkiss, E.L.5
De Marzo, A.6
Anders, R.7
Netto, G.8
Getnet, D.9
Bruno, T.C.10
Goldberg, M.V.11
Pardoll, D.M.12
Drake, C.G.13
|